middle.news
Imugene’s Azer-cel Trial Hits 81% Response Rate, Raises $25M to Fuel Growth
11:11am on Friday 31st of October, 2025 AEDT
•
Healthcare
Read Story
Imugene’s Azer-cel Trial Hits 81% Response Rate, Raises $25M to Fuel Growth
11:11am on Friday 31st of October, 2025 AEDT
Key Points
81% overall response rate in relapsed/refractory diffuse large B-cell lymphoma
Durable complete and partial responses with some patients cancer-free beyond 18 months
Trial expansion to CAR T naïve patients across multiple lymphoma types
Raised approximately $25 million via institutional placement and share purchase plan
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imugene (ASX:IMU)
OPEN ARTICLE